GIOTRIF® :
The 1st choice in 1st-line
Superior efficacy vs gefitinib and vs chemotherapy
demonstrated in 3 large trials in 1st-line EGFR M+ NSCLC1-4*
demonstrated in 3 large trials in 1st-line EGFR M+ NSCLC1-4*
GIOTRIF® followed by 3rd generation TKI in UpSwing Sequential Cohort
Document ID: PC-MY-102189
03/02/2022
Author: Boehringer Ingelheim
123,000
Views
100k 340
RELATED CONTENT
PC-MY-102189
Production date: February 2022
Production date: February 2022
